Surrogate Measures of Atherosclerosis and Implications for Evaluating Cardiovascular Risk - PowerPoint PPT Presentation

About This Presentation
Title:

Surrogate Measures of Atherosclerosis and Implications for Evaluating Cardiovascular Risk

Description:

Surrogate Measures of Atherosclerosis and Implications for Evaluating Cardiovascular Risk Nathan D. Wong, Ph.D., F.A.C.C. Associate Professor and Director – PowerPoint PPT presentation

Number of Views:119
Avg rating:3.0/5.0
Slides: 20
Provided by: Nathan341
Learn more at: http://www.bibalex.org
Category:

less

Transcript and Presenter's Notes

Title: Surrogate Measures of Atherosclerosis and Implications for Evaluating Cardiovascular Risk


1
Surrogate Measures of Atherosclerosis and
Implications for Evaluating Cardiovascular Risk
  • Nathan D. Wong, Ph.D., F.A.C.C.
  • Associate Professor and Director
  • Heart Disease Prevention Program
  • University of California, Irvine

2
Why use surrogate measures?
  • CHD events often occur with no clinical history
    and often normal risk factors (e.g., total
    cholesterol is a poor predictor)
  • Most heart attacks result from coronary lesions
    of less than 50 stenosis, often undetectable by
    traditional methods (exercise test, angiogram)
  • Subclinical atherosclerosis (carotid IMT, ABI,
    CAC?) predicts coronary events
  • Need to identify disease early enough to
    intervene to prevent clinical events

3
Features of Using Surrogate Measures of
Atherosclerosis
  • Use as intermediate endpoints rather than waiting
    until hard endpoints occur
  • May have implications for identifying and
    tracking earlier, subclinical disease
  • Compared to clinical event studies, studies of
    surrogate endpoints are lower cost, require fewer
    subjects, less-follow-up
  • Use to follow progression of disease and effects
    of medical intervention

4
Use of Coronary Angiography in Early Studies of
Surrogate Endpoints
  • The first trials of surrogate endpoints in the
    late 1980s involved coronary angiography
  • Cholesterol Lowering Atherosclerosis Study (CLAS)
    used a qualitative angiographic scoring in CABG
    pts studied 2 years apart.
  • FATS and Lifestyle Heart Trial Quantitative
    Coronary Angiography
  • Coronary angiography is expensive, may
    underestimate disease, examines only selected
    segments, limited to CAD patients

5
Primary Modalities for Measuring Atherosclerotic
Burden
  • Carotid B-mode ultrasonography intimal medial
    thicknesses
  • CT (EBT or multislice detectors) coronary
    calcium score or volume
  • Magnetic resonance imaging of carotid plaques
    vessel wall area
  • Intravascular ultrasound (invasive)
  • Brachial ultrasound

6
Other Noninvasive Measures Associated with
Cardiovascular Risk
  • Ankle-Brachial Index (ABI) for assessment of
    peripheral vascular disease
  • Echocardiographic left ventricular mass /
    hypertrophy, systolic (incl. Ejection fraction)
    and diastolic function
  • Pulse wave velocity / arterial compliance for
    assessing large artery stiffness

7
Carotid B-Mode Ultrasonography
  • Measurement of intimal medial thickness
  • Non-invasive, inexpensive, no radiation
  • Well-established as an indicator of
    cardiovascular risk from epidemiologic studies
  • Published clinical trials on utility of carotid
    IMT as measure of progression of atherosclerosis
    and effects of therapy

8
Carotid B-mode Ultrasonography Studies
  • Atherosclerosis Risk in Communities (ARIC) (Black
    and White subjects aged 45-64) RR 5.1 in women,
    1.9 in men for IMT gt 1 mm vs. lt 1 mm (Chambless
    et al, 1997).
  • Cardiovascular Health Study (CHS) (predominantly
    White, aged 65) MI or stroke rate 25 over 7
    years in those at highest quintile of combined
    IMT (OLeary et al. 1999)

9
Cardiovascular Health Study Combined
intimal-medial thickness predicts total MI and
stroke
10
Carotid IMT Clinical Trials
  • ACAPS showed lovastatin therapy in those aged
    40-79 with elevated LDL-C to be associated with
    regression in maximal IMT (Furberg et al., Circ
    1994 90 1679-87)
  • KAPS showed in men 45-65 a 45 lower rate of
    progression in those treated with pravastatin
    (Salonen et al., Circ 1995 92 1758-64).

11
Coronary Calcium Evaluation EBT and
Multidetector Scanners
  • Non-invasive, moderate cost, convenient
  • Detects location and quantity (score, mass,
    volume) of coronary calcium, estimating burden
    of atherosclerosis
  • Highly sensitive for angiographic disease,
    specificity variable depending on standard
  • Reproducibility good (best at higher scores) but
    similar in EBT vs. multidetector scanners
  • Artifact noise greater in EBT scanners

12
Coronary Calcium Scanning
  • Coronary Artery Scanning Protocol
  • Patient Preparation None
  • ECG Triggered to 60-70 of the R to R interval
  • 3mm contiguous scans
  • From carina to the apex

13
Interscan Variability Inversely Related to Mean
Calcium Score
14
Coronary Calcium Risk Factors and Prognosis
  • Coronary calcium quantity and prevalence
    increases with age relation to risk factors
    widely reported, by varies by study
  • Persons with coronary calcium more likely to
    begin healthful lifestyle behaviors
  • Amount of coronary calcium associated with
    greater risk of events from several selected
    cohort studies

15
Risk of Total Cardiovascular Events by Calcium
Quartile (n881)(compared to those with no
calcium age and risk-factor adjusted)Wong ND et
al., Am J Cardiol 86 295-8
16
Coronary Calcium Progression
Progression of Right coronary artery calcium
score over 5 years
1993 1995 1997
Calcium Score 56 Calcium Score 90 Calcium
Score 128 Volume Score 45 Volume Score 78
Volume Score 113
17
Coronary Calcium Progression
  • Studies of serial EBT scanning show annual
    progression of 22-52 per year
  • Observational study of statin therapy in 149
    patients showed calcium volume over 1 year
  • 52 progression in those not treated
  • regression (-7) alcium volume among those
    treated aggressively to LDL-C lt120 mg/dl, and
  • moderate progression (25) in those treated less
    aggressively (LDL-C gt120 mg/dl)
  • (Calister et al., NEJM 1998 339 1972-8).

18
Progression of Coronary Calcium (cont)
  • Other observational studies also show
    cholesterol-lowering or other therapy to relate
    to a reduced rate of progression (up to 50 in
    some cases).
  • Preliminary data relating progression to events
  • 269 asymp pts observed for 2.5 years. 20 of 22
    events occurred in those with progression of
    calcium (Raggi, Radiology 1999 213 351)
  • 225 asymp pts scanned avg 3 years apart 23 had
    events and showed increase in score of 35/yr,
    compared to 22 in those without events (Shah,
    Circulation 2000 102 II 604)

19
Flow Diagram Showing Interaction Between EBCT
Results and Clinical Management (Taylor et al.,
Western J Med 1999 171 339-41)
Click for larger picture
Write a Comment
User Comments (0)
About PowerShow.com